US 12,410,409 B2
Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
Yoshihiro Kawaoka, Middleton, WI (US); Gabriele Neumann, Madison, WI (US); and Makoto Ozawa, Kagoshima (JP)
Assigned to Wisconsin Alumni Research Foundation (WARF), Madison, WI (US)
Filed by Wisconsin Alumni Research Foundation (WARF), Madison, WI (US)
Filed on Jun. 8, 2022, as Appl. No. 17/835,830.
Application 17/835,830 is a division of application No. 16/694,748, filed on Nov. 25, 2019, granted, now 11,384,339.
Application 16/694,748 is a continuation of application No. 14/699,213, filed on Apr. 29, 2015, granted, now 10,513,692.
Application 14/699,213 is a continuation of application No. 13/594,611, filed on Aug. 24, 2012, granted, now 9,101,653.
Claims priority of provisional application 61/527,935, filed on Aug. 26, 2011.
Prior Publication US 2023/0348864 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 7/00 (2006.01); A61K 35/76 (2015.01); A61K 39/09 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)
CPC C12N 7/00 (2013.01) [A61K 35/76 (2013.01); A61K 39/092 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); G01N 33/56983 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/543 (2013.01); A61K 2039/70 (2013.01); C12N 2760/16121 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16143 (2013.01); C12N 2760/16151 (2013.01); C12N 2760/16171 (2013.01); G01N 2333/11 (2013.01)] 14 Claims
 
1. A vaccine comprising an effective amount of a biologically contained influenza A virus comprising: 8 different viral segments including a PA viral segment, a PB1 viral segment, a mutant PB2 viral segment, a HA viral segment, a NA viral segment, a NP viral segment, a M (M1 and M2) viral segment, and a NS (NS1 and NS2) viral segment, wherein the mutant PB2 viral segment includes 5′ and 3′ incorporation sequences including 3′ or 5′ coding and non-coding incorporation sequences flanking a heterologous nucleotide sequence comprising a therapeutic or prophylactic gene and does not include contiguous sequences corresponding to sequences encoding a functional PB2, and wherein the HA viral segment encodes one of subtypes H1 to H16.